Novo Nordisk was the pioneer in introducing GLP-1 weight loss drugs, but Eli Lilly has now taken the lead in this emerging space. Both companies are respected pharmaceutical giants, but Eli Lilly’s stock has been on the rise while Novo Nordisk’s has been falling, all due to GLP-1 drugs. Despite the quick weight loss benefits of these drugs, there are concerns about weight regain and muscle loss. However, customers are eager for these drugs, prompting other pharmaceutical companies like Pfizer to enter the GLP-1 market. Eli Lilly’s stock may be expensive, leading investors to consider Novo Nordisk or the undervalued Pfizer as potential investment opportunities.

Read more at Nasdaq: Is It Time to Dump Your Shares of Eli Lilly?